API | rabacfosadine

rabacfosadine Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Rabacfosadine, sold under the brand name Tanovea, is a guanine nucleotide analog used for the treatment of lymphoma in dogs. The drug was granted conditional approval by the U.S. Food and Drug Administration under application number 141-475 for use in treating canine lymphoma in December 2016 pending a full demonstration of effectiveness, and became the first drug to receive full approval for the treatment of canine lymphoma in July 2021. ^Wikipedia

Chemistry

SMILES: CCOC(=O)[C@H](C)NP(=O)(COCCn1cnc2c(NC3CC3)nc(N)nc12)N[C@@H](C)C(=O)OCC
InChIKey: ANSPEDQTHURSFQ-KBPBESRZSA-N
Mol. Mass: 526.54
ALogP: 1.23 Partition coefficient
ChEMBL Molecule:
rabacfosadine

More Chemistry

Pharmacology

Mechanism of Action:
- DNA polymerase nu (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

gs-9219 | rabacfosadine | vdc-1101

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue